Inhibikase Therapeutics, Inc.
IKTHealthcare|Biotechnology|US
$1.50
+0.06 (+4.17%)
DCF Value
$1.41
Tangible Book / Share
$0.88
Cash / Share
$0.91
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07365332 An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | P3 | Recruiting | 486 | RCT, Double-blind | IKT-001, Placebo |
| NCT07632898 Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension (PAH) | P3 | Not Yet Recruiting | 484 | Open-label | IKT-001 |
| NCT06643143 A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | P2 | Withdrawn | — | RCT, Double-blind | IkT-001Pro, Placebo |
| NCT05623774 A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg | CML | P1 | Completed | 64 | Open-label | Imatinib Mesylate, IkT-001Pro |